Shopping Cart

Your shopping cart is currently empty

Ragaglitazar

Name: Ragaglitazar
Brand: TargetMol
SKU: T28501
Price: 639 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T28501Cas No. 222834-30-2

Alias NNC61-0029, NNC-61-0029, NNC 61-0029, NN-622, NN 622, (-)-DRF-2725

Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.

Ragaglitazar

Copy Product Info

🥰Excellent

Purity: 98.56%

Catalog No. T28501Alias NNC61-0029, NNC-61-0029, NNC 61-0029, NN-622, NN 622, (-)-DRF-2725Cas No. 222834-30-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$639	In Stock	In Stock
5 mg	$1,370	In Stock	In Stock
25 mg	$2,230	In Stock	In Stock
50 mg	$2,780	In Stock	In Stock
100 mg	$3,700	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.56%

ee:96.428%

Appearance:Solid

Color:Yellow

Resource Download

COA CSFC HNMR LCMS ORP

Product Introduction

Ragaglitazar AI Summary

Ragaglitazar exhibits bioactivity related to the activation of peroxisome proliferator-activated receptors (PPARs) alpha and gamma. It shows significant affinity and activation potency in human cells, with an EC50 of approximately 3210.0 nM and a maximum activation of 97.0% for PPAR alpha, and an EC50 of around 570.0 nM with a maximum activation of 117.0% for PPAR gamma. Additionally, it demonstrates a lower activation of PPAR delta with a maximum activation of 7.0%. The compound's receptor binding affinity is quantified with IC50 values of 980.0 nM for PPAR alpha and 92.0 nM for PPAR gamma. Pharmacokinetic studies in Male Wistar rats reveal parameters such as AUC, Cmax, Tmax, Kel, T1/2, F, Vd, and Cl following both oral and intravenous administration. Moreover, Ragaglitazar has been assessed for its potential to cause drug-induced liver injury (DILI) and was categorized as DILI negative in the Drug Induced Liver Injury Prediction System (DILIps) validation dataset. These comprehensive characteristics suggest that Ragaglitazar holds potential as a modulator of PPAR pathways involved in metabolism and inflammation..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
In vitro	METHODS: A comparative dose-response study of PPARγ and PPARα was performed using Ragaglitazar (NNC-61-0029) (0.1, 1, 10, 100 nM). RESULTS Ragaglitazar (NNC-61-0029) showed significant activation of both isoforms. Ragaglitazar showed weaker potency against PPARγ (EC50=324 nm) and more potent activation of PPARα (EC50=270 nm). [1]
In vivo	METHODS: SD rats fed a high-fat diet were treated with Ragaglitazar (NNC-61-0029) (0.1, 0.3, 1, 10, 30 mg/kg) to observe the improvement of blood lipid levels in rats. RESULTS Rats showed a dose-dependent improvement in plasma lipid levels, and plasma Apo CIII levels were significantly reduced in ragaglitazar (10 mg/kg) (P<0.05). [1]
Synonyms	NNC61-0029, NNC-61-0029, NNC 61-0029, NN-622, NN 622, (-)-DRF-2725

Chemical Properties

Molecular Weight	419.47
Formula	C₂₅H₂₅NO₅
Cas No.	222834-30-2
Smiles	C(COC1=CC=C(C[C@H](OCC)C(O)=O)C=C1)N2C=3C(OC=4C2=CC=CC4)=CC=CC3
Relative Density.	1.241 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (119.2 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (5.96 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3840 mL	11.9198 mL	23.8396 mL	119.1980 mL
5 mM	0.4768 mL	2.3840 mL	4.7679 mL	23.8396 mL
10 mM	0.2384 mL	1.1920 mL	2.3840 mL	11.9198 mL
20 mM	0.1192 mL	0.5960 mL	1.1920 mL	5.9599 mL
50 mM	0.0477 mL	0.2384 mL	0.4768 mL	2.3840 mL
100 mM	0.0238 mL	0.1192 mL	0.2384 mL	1.1920 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc